Zobrazeno 1 - 10
of 117
pro vyhledávání: '"Rosario García‐Campelo"'
Autor:
Niki Karachaliou, Jordi Codony-Servat, Cristina Teixidó, Sara Pilotto, Ana Drozdowskyj, Carles Codony-Servat, Ana Giménez-Capitán, Miguel Angel Molina-Vila, Jordi Bertrán-Alamillo, Radj Gervais, Bartomeu Massuti, Teresa Morán, Margarita Majem, Enriqueta Felip, Enric Carcereny, Rosario García-Campelo, Santiago Viteri, María González-Cao, Daniela Morales-Espinosa, Alberto Verlicchi, Elisabetta Crisetti, Imane Chaib, Mariacarmela Santarpia, José Luis Ramírez, Joaquim Bosch-Barrera, Andrés Felipe Cardona, Filippo de Marinis, Guillermo López-Vivanco, José Miguel Sánchez, Alain Vergnenegre, José Javier Sánchez Hernández, Isabella Sperduti, Emilio Bria, Rafael Rosell
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-2 (2023)
Externí odkaz:
https://doaj.org/article/907f95952a6f451dab4695071025b8b3
Autor:
Estela Sánchez‐Herrero, Roberto Serna‐Blasco, Vadym Ivanchuk, Rosario García‐Campelo, Manuel Dómine Gómez, José M. Sánchez, Bartomeu Massutí, Noemi Reguart, Carlos Camps, Sandra Sanz‐Moreno, Silvia Calabuig‐Fariñas, Eloísa Jantus‐Lewintre, Magdalena Arnal, Dietmar Fernández‐Orth, Virginia Calvo, Víctor González‐Rumayor, Mariano Provencio, Atocha Romero
Publikováno v:
Molecular Oncology, Vol 15, Iss 9, Pp 2363-2376 (2021)
Despite impressive and durable responses, nonsmall cell lung cancer (NSCLC) patients treated with anaplastic lymphoma kinase (ALK) inhibitors (ALK‐Is) ultimately progress due to development of resistance. Here, we have evaluated the clinical utilit
Externí odkaz:
https://doaj.org/article/f8857d8e937348c0ac60929a958c48fe
Autor:
Lourdes Gutiérrez, Ana Royuela, Enric Carcereny, Rafael López-Castro, Delvys Rodríguez-Abreu, Bartomeu Massuti, José Luis González-Larriba, Rosario García-Campelo, Joaquim Bosch-Barrera, María Guirado, Carlos Camps, Manuel Dómine, Reyes Bernabé, Joaquín Casal, Juana Oramas, Ana Laura Ortega, Mª. Angeles Sala, Airam Padilla, David Aguiar, Oscar Juan-Vidal, Remei Blanco, Edel del Barco, Natividad Martínez-Banaclocha, Gretel Benítez, Blanca de Vega, Ainhoa Hernández, Maria Saigi, Fernando Franco, Mariano Provencio
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background There is a lack of useful diagnostic tools to identify EGFR mutated NSCLC patients with long-term survival. This study develops a prognostic model using real world data to assist clinicians to predict survival beyond 24 months. Me
Externí odkaz:
https://doaj.org/article/233d05bfad794aa8b762c296fe046b5c
Autor:
Fernando Franco, Enric Carcereny, Maria Guirado, Ana L Ortega, Rafael López-Castro, Delvys Rodríguez-Abreu, Rosario García-Campelo, Edel Del Barco, Oscar Juan, Francisco Aparisi, Jose L González-Larriba, Manuel Domine, Jose M Trigo, Manuel Cobo, Sara Cerezo, Julia Calzas, Bartomeu Massutí, Joaquim Bosch-Barrera, Paola García Coves, Marta Domènech, Mariano Provencio
Publikováno v:
PLoS ONE, Vol 16, Iss 6, p e0251761 (2021)
BackgroundSmall-cell lung cancer (SCLC) is an aggressive disease with high metastatic potential and poor prognosis. Due to its low prevalence, epidemiological and clinical information of SCLC patients retrieved from lung cancer registries is scarce.P
Externí odkaz:
https://doaj.org/article/e996f890d27d40b4b39cabb6efbcd2ad
Autor:
Esther Conde, Ana Suárez-Gauthier, Amparo Benito, Pilar Garrido, Rosario García-Campelo, Michele Biscuola, Luis Paz-Ares, David Hardisson, Javier de Castro, M Carmen Camacho, Delvys Rodriguez-Abreu, Ihab Abdulkader, Josep Ramirez, Noemí Reguart, Marta Salido, Lara Pijuán, Edurne Arriola, Julián Sanz, Victoria Folgueras, Noemí Villanueva, Javier Gómez-Román, Manuel Hidalgo, Fernando López-Ríos
Publikováno v:
PLoS ONE, Vol 9, Iss 9, p e107200 (2014)
BackgroundBased on the excellent results of the clinical trials with ALK-inhibitors, the importance of accurately identifying ALK positive lung cancer has never been greater. However, there are increasing number of recent publications addressing disc
Externí odkaz:
https://doaj.org/article/a2ee3e16eccc4c4487381ac1367b8191
Autor:
Mariano Provencio, Manuel Cobo, Delvys Rodriguez-Abreu, Virginia Calvo, Enric Carcereny, Alexandra Cantero, Reyes Bernabé, Gretel Benitez, Rafael López Castro, Bartomeu Massutí, Edel del Barco, Rosario García Campelo, Maria Guirado, Carlos Camps, Ana Laura Ortega, Jose Luis González Larriba, Alfredo Sánchez, Joaquín Casal, M. Angeles Sala, Oscar Juan-Vidal, Joaquim Bosch-Barrera, Juana Oramas, Manuel Dómine, Jose Manuel Trigo, Remei Blanco, Julia Calzas, Idoia Morilla, Airam Padilla, Joao Pimentao, Pedro A. Sousa, Maria Torrente
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background The survival of patients with lung cancer has substantially increased in the last decade by about 15%. This increase is, basically, due to targeted therapies available for advanced stages and the emergence of immunotherapy itself.
Externí odkaz:
https://doaj.org/article/0111fe9f31fa49208eab155d42059c73
Autor:
Amelia Insa, Mariano Provencio, Bartomeu Massutí, Margarita Majem, Delvys Rodriguez-Abreu, Manuel Cobo, Manuel Dómine, Ernest Nadal, Belén Sierra-Rodero, Alberto Cruz-Bermúdez, Alex Martinez-Marti, Javier De Castro Carpeño, Guillermo López Vivanco, Edel Del Barco, Nuria Viñolas, Isidoro Barneto Aranda, Marta Casarrubios, Atocha Romero, Reyes Bernabe, María del Rosario García-Campelo, Martín Lázaro-Quintela, Cristina Martinez-Toledo, Ismael Fernández-Miranda, Roberto Serna-Blanco, Virginia Calvo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
Background Neoadjuvant chemoimmunotherapy for non-small cell lung cancer (NSCLC) has improved pathological responses and survival rates compared with chemotherapy alone, leading to Food and Drug Administration (FDA) approval of nivolumab plus chemoth
Externí odkaz:
https://doaj.org/article/536d1ef3434247f3bec7c014036712de
Autor:
Raquel Laza‐Briviesca, Alberto Cruz‐Bermúdez, Ernest Nadal, Amelia Insa, María del Rosario García‐Campelo, Gerardo Huidobro, Manuel Dómine, Margarita Majem, Delvys Rodríguez‐Abreu, Alex Martínez‐Martí, Javier De Castro Carpeño, Manuel Cobo, Guillermo López Vivanco, Edel Del Barco, Reyes Bernabé Caro, Nuria Viñolas, Isidoro Barneto Aranda, Santiago Viteri, Bartomeu Massuti, Marta Casarrubios, Belén Sierra‐Rodero, Carlos Tarín, Aránzazu García‐Grande, Cara Haymaker, Ignacio I. Wistuba, Atocha Romero, Fernando Franco, Mariano Provencio
Publikováno v:
Clinical and Translational Medicine, Vol 11, Iss 7, Pp n/a-n/a (2021)
Abstract Background Immunotherapy is being tested in early‐stage non‐small cell lung cancer (NSCLC), and achieving higher rates of complete pathological responses (CPR) as compared to standard of care. Early identification of CPR patients has vit
Externí odkaz:
https://doaj.org/article/0ad46e49a0734ef1b5f505f363328cb9
Autor:
Mariano Provencio, Roberto Serna-Blasco, Ernest Nadal, Amelia Insa, M. Rosario García-Campelo, Joaquín Casal Rubio, Manuel Dómine, Margarita Majem, Delvys Rodríguez-Abreu, Alex Martínez-Martí, Javier De Castro Carpeño, Manuel Cobo, Guillermo López Vivanco, Edel Del Barco, Reyes Bernabé Caro, Nuria Viñolas, Isidoro Barneto Aranda, Santiago Viteri, Eva Pereira, Ana Royuela, Virginia Calvo, Javier Martín-López, Francisco García-García, Marta Casarrubios, Fernando Franco, Estela Sánchez-Herrero, Bartomeu Massuti, Alberto Cruz-Bermúdez, Atocha Romero
Publikováno v:
JOURNAL OF CLINICAL ONCOLOGY
r-CIPF. Repositorio Institucional Producción Científica del Centro de Investigación Principe Felipe (CIPF)
Universitat Rovira i virgili (URV)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Scientia
r-CIPF. Repositorio Institucional Producción Científica del Centro de Investigación Principe Felipe (CIPF)
Universitat Rovira i virgili (URV)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Scientia
PURPOSE Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in resectable non–small-cell lung cancer (NSCLC) in the NADIM trial (ClinicalTrials.gov identifier: NCT03081689 ). The 3-year overall survival (OS) and circulating tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ea7330b9d5f399beeb1fe0adeeb286f
https://doi.org/10.1200/jco.21.02660
https://doi.org/10.1200/jco.21.02660
Autor:
Edurne Arriola, Reyes Bernabé, Rosario García Campelo, Michele Biscuola, Ana Belén Enguita, Fernando López-Ríos, Rafael Martínez, Laura Mezquita, Sarai Palanca, María Jesús Pareja, Jon Zugazagoitia, Natalia Arrabal, J. Francisco García, David Carcedo, Enrique de Álava
Publikováno v:
JCO Precision Oncology.
PURPOSE The aim of this study was to assess the cost-effectiveness of using next-generation sequencing (NGS) versus single-gene testing (SgT) for the detection of genetic molecular subtypes and oncogenic markers in patients with advanced non–small-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b438be591a49314a7b138cc63ce4f6c2
https://doi.org/10.1200/po.22.00546
https://doi.org/10.1200/po.22.00546